Understanding the United States Chronic Lymphocytic Leukemia (CLL) Patient Journey to Make Informed Business Decisions, Identify Opportunities, and Understand Potential Challenges
October 25, 2024 04:07 ET
|
Research and Markets
Dublin, Oct. 25, 2024 (GLOBE NEWSWIRE) -- The "Chronic Lymphocytic Leukemia (CLL) in the United States: Understanding the CLL Patient Experience" report has been added to ResearchAndMarkets.com's...
Understanding the United States Chronic Myeloid Leukemia (CML) Patient Experience to Make Informed Business Decisions, Identify Opportunities, and Understand Potential Challenges
October 25, 2024 04:06 ET
|
Research and Markets
Dublin, Oct. 25, 2024 (GLOBE NEWSWIRE) -- The "Chronic Myeloid Leukemia (CML) in the United States: Understanding the CML Patient Experience" report has been added to ResearchAndMarkets.com's...
United States Chronic Myeloid Leukemia (CML) Patient Quality of Life & Information-Seeking Behaviors Insights Report 2024
October 24, 2024 04:25 ET
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Chronic Myeloid Leukemia (CML) in the United States: Quality of Life & Information-Seeking Behaviors" report has been added to ...
Smart Immune détermine la dose recommandée de SMART101 pour ses essais cliniques en oncologie
October 23, 2024 01:01 ET
|
Smart Immune
La phase I d'escalade de dose de ReSET-02 chez des adultes souffrant de cancers hématologiques est terminée.Le segment randomisé de la phase II de cet essai est en cours.Aucune toxicité limitant la...
Smart Immune Announces Recommended SMART101 Dose for Adult Cancer Proof-of-Concept Trials
October 23, 2024 01:01 ET
|
Smart Immune
ReSET-02 dose escalation Phase I is completedPhase II PoC randomized segment is starting No dose-limiting toxicities, no safety or tolerability issuesThe highest dose is to be used in both...
NMDP℠ Raises $1.1 Million at Annual Gala Expanding Access to Life-Saving Cell Therapies
October 03, 2024 09:00 ET
|
NMDP
NMDP, a global nonprofit leader in cell therapy, raised $1.1 million during its 17th annual fundraising gala expanding access to life-saving treatments.
Acute Myeloid Leukemia (AML) in the United States: Primary Insights Into the Patient Experience
September 26, 2024 04:25 ET
|
Research and Markets
Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Acute Myeloid Leukemia (AML) in the United States: A Review of 2023 - Key Insights into Treatment Awareness & Satisfaction" report has been added...
Chronic Lymphocytic Leukemia (CLL) in the United States: A Review of 2023 - Key Insights into Treatment Awareness & Satisfaction
September 26, 2024 04:23 ET
|
Research and Markets
Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Chronic Lymphocytic Leukemia (CLL) in the United States: A Review of 2023 - Key Insights into Treatment Awareness & Satisfaction" report has been...
U.S. Chronic Myeloid Leukemia (CML) Treatment Awareness & Satisfaction Report - What Medications Have Patients Discussed With Their HCP?
September 26, 2024 04:21 ET
|
Research and Markets
Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Chronic Myeloid Leukemia (CML) in the United States: A Review of 2023 - Key Insights into Treatment Awareness & Satisfaction" report has been...
U.S. Myelodysplastic Syndromes (MDS) Patient Insights Report: HCP Treatment Discussions, Treatment Satisfaction & Awareness, Clinical Trial Interest, and Much More
September 26, 2024 04:20 ET
|
Research and Markets
Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Myelodysplastic Syndromes (MDS) in the United States: A Review of 2023 - Key Insights into Treatment Awareness & Satisfaction" report has been...